Which has preferable earnings and valuation, INCY or ABBV?

AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 5.00 $1.29B $7.85 16.15 AbbVie $61.16B 7.40 $4.23B $3.54 72.39

Is INCY or ABBV more profitable?

Incyte has a net margin of 27.71% compared to AbbVie's net margin of 9.80%. Incyte's return on equity of 29.93% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% AbbVie 9.80% -422.07% 14.34%

Does the media prefer INCY or ABBV?

In the previous week, AbbVie had 136 more articles in the media than Incyte. MarketBeat recorded 150 mentions for AbbVie and 14 mentions for Incyte. AbbVie's average media sentiment score of 1.39 beat Incyte's score of 1.20 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 125 Very Positive mention(s) 9 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Positive

Does the media refer more to REGN or INCY?

In the previous week, Regeneron Pharmaceuticals had 30 more articles in the media than Incyte. MarketBeat recorded 44 mentions for Regeneron Pharmaceuticals and 14 mentions for Incyte. Incyte's average media sentiment score of 1.20 beat Regeneron Pharmaceuticals' score of 0.52 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 15 Very Positive mention(s) 4 Positive mention(s) 20 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Incyte 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, INCY or ARGX?

argenex has lower revenue, but higher earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 5.00 $1.29B $7.85 16.15 argenex $4.25B 15.21 $1.29B $26.04 39.68

Is INCY or ARGX more profitable?

argenex has a net margin of 32.19% compared to Incyte's net margin of 27.71%. argenex's return on equity of 43.59% beat Incyte's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% argenex 32.19% 43.59% 36.66%

Does the media refer more to INCY or ARGX?

In the previous week, argenex had 1 more articles in the media than Incyte. MarketBeat recorded 15 mentions for argenex and 14 mentions for Incyte. Incyte's average media sentiment score of 1.20 beat argenex's score of 0.59 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 2 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, MRNA or INCY?

Incyte has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 29.89 -$2.82B -$7.99 N/A Incyte $5.14B 5.00 $1.29B $7.85 16.15

Is MRNA or INCY more profitable?

Incyte has a net margin of 27.71% compared to Moderna's net margin of -141.43%. Incyte's return on equity of 29.93% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Incyte 27.71% 29.93% 22.88%

Does the media refer more to MRNA or INCY?

In the previous week, Moderna had 51 more articles in the media than Incyte. MarketBeat recorded 65 mentions for Moderna and 14 mentions for Incyte. Incyte's average media sentiment score of 1.20 beat Moderna's score of 0.58 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 21 Very Positive mention(s) 14 Positive mention(s) 11 Neutral mention(s) 5 Negative mention(s) 4 Very Negative mention(s) Positive Incyte 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, NTRA or INCY?

Incyte has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 20.51 -$208.16M -$1.36 N/A Incyte $5.14B 5.00 $1.29B $7.85 16.15

Is NTRA or INCY more profitable?

Incyte has a net margin of 27.71% compared to Natera's net margin of -7.11%. Incyte's return on equity of 29.93% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Natera -7.11% -11.38% -7.87% Incyte 27.71% 29.93% 22.88%

Does the media favor NTRA or INCY?

In the previous week, Natera had 5 more articles in the media than Incyte. MarketBeat recorded 19 mentions for Natera and 14 mentions for Incyte. Incyte's average media sentiment score of 1.20 beat Natera's score of 1.07 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Incyte (INCY) Competitors

$126.75 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

INCY vs. ABBV, REGN, ARGX, MRNA, and NTRA

Should you buy Incyte stock or one of its competitors? Incyte's main competitors and comparable companies include AbbVie (ABBV), Regeneron Pharmaceuticals (REGN), argenex (ARGX), Moderna (MRNA), and Natera (NTRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Incyte compare to AbbVie?

Incyte (NASDAQ:INCY) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

97.0% of Incyte shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, AbbVie had 136 more articles in the media than Incyte. MarketBeat recorded 150 mentions for AbbVie and 14 mentions for Incyte. AbbVie's average media sentiment score of 1.39 beat Incyte's score of 1.20 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	125 Very Positive mention(s)	9 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

Incyte presently has a consensus target price of $124.05, suggesting a potential downside of 2.13%. AbbVie has a consensus target price of $275.95, suggesting a potential upside of 7.68%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	12 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.54
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

Incyte has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	5.00	$1.29B	$7.85	16.15
AbbVie	$61.16B	7.40	$4.23B	$3.54	72.39

Incyte has a net margin of 27.71% compared to AbbVie's net margin of 9.80%. Incyte's return on equity of 29.93% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
AbbVie	9.80%	-422.07%	14.34%

Summary

AbbVie beats Incyte on 10 of the 17 factors compared between the two stocks.

How does Incyte compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Incyte (NASDAQ:INCY) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Regeneron Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Incyte has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

In the previous week, Regeneron Pharmaceuticals had 30 more articles in the media than Incyte. MarketBeat recorded 44 mentions for Regeneron Pharmaceuticals and 14 mentions for Incyte. Incyte's average media sentiment score of 1.20 beat Regeneron Pharmaceuticals' score of 0.52 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	15 Very Positive mention(s)	4 Positive mention(s)	20 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Incyte	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals currently has a consensus price target of $800.36, indicating a potential downside of 3.31%. Incyte has a consensus price target of $124.05, indicating a potential downside of 2.13%. Given Incyte's higher probable upside, analysts clearly believe Incyte is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58
Incyte	0 Sell rating(s)	12 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.54

Regeneron Pharmaceuticals has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.94	$4.50B	$40.46	20.46
Incyte	$5.14B	5.00	$1.29B	$7.85	16.15

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Incyte's net margin of 27.71%. Incyte's return on equity of 29.93% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Incyte	27.71%	29.93%	22.88%

Summary

Regeneron Pharmaceuticals beats Incyte on 9 of the 17 factors compared between the two stocks.

How does Incyte compare to argenex?

Incyte (NASDAQ:INCY) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

argenex has a net margin of 32.19% compared to Incyte's net margin of 27.71%. argenex's return on equity of 43.59% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
argenex	32.19%	43.59%	36.66%

Incyte presently has a consensus price target of $124.05, indicating a potential downside of 2.13%. argenex has a consensus price target of $1,158.61, indicating a potential upside of 12.14%. Given argenex's stronger consensus rating and higher possible upside, analysts plainly believe argenex is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	12 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.54
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88

Incyte has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

In the previous week, argenex had 1 more articles in the media than Incyte. MarketBeat recorded 15 mentions for argenex and 14 mentions for Incyte. Incyte's average media sentiment score of 1.20 beat argenex's score of 0.59 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	2 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Incyte shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

argenex has lower revenue, but higher earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	5.00	$1.29B	$7.85	16.15
argenex	$4.25B	15.21	$1.29B	$26.04	39.68

Summary

argenex beats Incyte on 12 of the 17 factors compared between the two stocks.

How does Incyte compare to Moderna?

Moderna (NASDAQ:MRNA) and Incyte (NASDAQ:INCY) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

In the previous week, Moderna had 51 more articles in the media than Incyte. MarketBeat recorded 65 mentions for Moderna and 14 mentions for Incyte. Incyte's average media sentiment score of 1.20 beat Moderna's score of 0.58 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	21 Very Positive mention(s)	14 Positive mention(s)	11 Neutral mention(s)	5 Negative mention(s)	4 Very Negative mention(s)	Positive
Incyte	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Incyte has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

75.3% of Moderna shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 16.2% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Moderna currently has a consensus price target of $76.72, suggesting a potential downside of 47.29%. Incyte has a consensus price target of $124.05, suggesting a potential downside of 2.13%. Given Incyte's stronger consensus rating and higher probable upside, analysts clearly believe Incyte is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Incyte	0 Sell rating(s)	12 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.54

Incyte has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	29.89	-$2.82B	-$7.99	N/A
Incyte	$5.14B	5.00	$1.29B	$7.85	16.15

Incyte has a net margin of 27.71% compared to Moderna's net margin of -141.43%. Incyte's return on equity of 29.93% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Incyte	27.71%	29.93%	22.88%

Summary

Incyte beats Moderna on 14 of the 17 factors compared between the two stocks.

How does Incyte compare to Natera?

Natera (NASDAQ:NTRA) and Incyte (NASDAQ:INCY) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Natera currently has a consensus target price of $319.38, suggesting a potential downside of 2.68%. Incyte has a consensus target price of $124.05, suggesting a potential downside of 2.13%. Given Incyte's higher possible upside, analysts clearly believe Incyte is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82
Incyte	0 Sell rating(s)	12 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.54

Incyte has a net margin of 27.71% compared to Natera's net margin of -7.11%. Incyte's return on equity of 29.93% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Incyte	27.71%	29.93%	22.88%

99.9% of Natera shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 5.1% of Natera shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Incyte has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.51	-$208.16M	-$1.36	N/A
Incyte	$5.14B	5.00	$1.29B	$7.85	16.15

In the previous week, Natera had 5 more articles in the media than Incyte. MarketBeat recorded 19 mentions for Natera and 14 mentions for Incyte. Incyte's average media sentiment score of 1.20 beat Natera's score of 1.07 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	14 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Natera has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market. Comparatively, Incyte has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Summary

Incyte beats Natera on 10 of the 17 factors compared between the two stocks.

Get Incyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INCY vs. The Competition

Export

Metric	Incyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$25.69B	$4.00B	$7.21B	$12.89B
Dividend Yield	N/A	3.60%	2.54%	9.13%
P/E Ratio	16.15	12.71	273.82	25.45
Price / Sales	5.00	1,332.43	621.41	100.89
Price / Cash	20.51	45.00	28.92	35.62
Price / Book	4.82	16.42	11.01	6.39
Net Income	$1.29B	-$22.85M	$3.49B	$358.69M
7 Day Performance	2.86%	1.41%	1.65%	0.22%
1 Month Performance	5.13%	5.98%	4.44%	-0.10%
1 Year Performance	46.30%	49.29%	24.21%	14.04%

Incyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INCY Incyte	3.6354 of 5 stars	$126.75 flat	$124.05 -2.1%	+46.3%	$25.69B	$5.14B	16.15	2,844	Positive News
ABBV AbbVie	4.605 of 5 stars	$256.95 +0.6%	$275.95 +7.4%	+20.7%	$451.38B	$61.16B	72.58	57,000	Positive News
REGN Regeneron Pharmaceuticals	4.0746 of 5 stars	$799.08 +0.6%	$800.36 +0.2%	+44.4%	$81.77B	$14.34B	19.75	15,410
ARGX argenex	4.0361 of 5 stars	$1,031.66 +0.8%	$1,158.61 +12.3%	+37.6%	$64.01B	$4.25B	39.62	1,863	Analyst Upgrade
MRNA Moderna	1.4667 of 5 stars	$140.34 +1.7%	$80.53 -42.6%	+479.0%	$55.09B	$1.94B	N/A	4,700	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INCY) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incyte (INCY) Competitors